Work

Randomized, Phase II Trial of Pemetrexed and Carboplatin with or without Enzastaurin versus Docetaxel and Carboplatin as First-Line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer

Year: 2010

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Journal of Thoracic Oncology

DOI: 10.1097/jto.0b013e3181fd42eb

Authors: Mark A. Socinski, Robert N. Raju, Thomas Stinchcombe, Darren M. Kocs, Linda S. Couch, David Barrera, Steven R. Rousey, Janak K. Choksi, Robert Jotte, Debra A. Patt, Phillip O. Periman, Howard R. Schlossberg, Charles H. Weissman, Yunfei Wang, Lina Asmar, Sharon Pritchard, Jane Bromund, Guangbin Peng, Joseph Treat, Coleman K. Obasaju

Institutions: University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, The US Oncology Network, Eli Lilly (United States)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: Eli Lilly and Company

OpenAlex ID: W2031871042

FWCI: 3.189

Cites: 44

Cited by: 35

Related to: 10